Olaratumab - Eli Lilly

Drug Profile

Olaratumab - Eli Lilly

Alternative Names: IMC-3G3; Lartruvo; LY 3012207

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Soft tissue sarcoma
  • Phase I/II Pancreatic cancer
  • Phase I Solid tumours
  • No development reported Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 04 Oct 2018 Institute for Clinical Oncological Research plans a phase II trial in Soft tissue sarcoma (Second line therapy or greater, Late stage disease, Metastatic disease, Unresectable) in Germany (IV) (NCT03698227)
  • 05 Jul 2018 Eli Lilly completes a phase I trial for Soft tissue sarcoma (Combination therapy) in USA, France, Italy, Spain and the United Kingdom (IV) (NCT02783599)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top